

Emanuele Perrone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2844278/publications.pdf>

Version: 2024-02-01

45
papers

836
citations

430874

18
h-index

501196

28
g-index

45
all docs

45
docs citations

45
times ranked

989
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 50.	8.6	15
2	The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method. <i>Gynecologic Oncology</i> , 2022, 165, 585-593.	1.4	10
3	Laparoscopic vs. robotic-assisted laparoscopy in endometrial cancer staging: large retrospective single-institution study. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e45.	2.2	20
4	A Multicentric Randomized Trial to Evaluate the ROLE of Uterine MANipulator on Laparoscopic/Robotic HYsterectomy for the Treatment of Early-Stage Endometrial Cancer: The ROMANHY Trial. <i>Frontiers in Oncology</i> , 2021, 11, 720894.	2.8	11
5	Sexual Function following Laparoscopic versus Transvaginal Closure of the Vaginal Vault after Laparoscopic Hysterectomy: Secondary Analysis of a Randomized Trial by the Italian Society of Gynecological Endoscopy Using a Validated Questionnaire. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 186-194.	0.6	15
6	Feasibility and perioperative outcomes of percutaneous-assisted laparoscopic hysterectomy: A multicentric Italian experience. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 245, 181-185.	1.1	21
7	Sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. <i>Molecular Oncology</i> , 2020, 14, 645-656.	4.6	20
8	In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2020, 156, 430-438.	1.4	18
9	Percutaneous-assisted vs mini-laparoscopic hysterectomy: comparison of ultra-minimally invasive approaches. <i>Updates in Surgery</i> , 2020, 73, 2347-2354.	2.0	9
10	Percutaneous-Assisted versus Laparoscopic Hysterectomy: A Prospective Comparison. <i>Gynecologic and Obstetric Investigation</i> , 2020, 85, 318-326.	1.6	5
11	Percutaneous approach in early-stage ovarian cancer staging. <i>Gynecology and Pelvic Medicine</i> , 2020, 3, 29-29.	0.1	0
12	Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 118.	2.8	30
13	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. <i>Scientific Reports</i> , 2020, 10, 973.	3.3	31
14	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	1.8	32
15	Ovarian cyst enucleation with Senhance robotic platform. <i>Asvide</i> , 2020, 7, 225-225.	0.0	0
16	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
17	PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib. <i>Gynecologic Oncology</i> , 2019, 155, 144-150.	1.4	28
18	Technological innovation and personalized surgical treatment for early-stage endometrial cancer patients: A prospective multicenter Italian experience to evaluate the novel percutaneous approach. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 234, 218-222.	1.1	33

#	ARTICLE	IF	CITATIONS
19	51â€¦In vitro and in vivo activity of sacituzumab govitecan, in ovarian cancer. , 2019, , .		0
20	93â€¦Sacituzumab govitecan in uterine and ovarian carcinosarcomas. , 2019, , .		0
21	Inguino-abdominal combined approach for laterally extended pelvic resection: a step by step procedure. International Journal of Gynecological Cancer, 2019, 29, 444-445.	2.5	2
22	PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers. Gynecologic Oncology, 2019, 153, 158-164.	1.4	13
23	Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.. Journal of Clinical Oncology, 2019, 37, e17028-e17028.	1.6	1
24	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0
25	Abstract 4819: Sacituzumab Govitecan (IMMU-132) in uterine serous carcinoma. , 2019, , .		0
26	Why Some Women Develop Cesarean Scar Defect (CSD)? . , 2018, , 401-407.		0
27	3Âmm Senhance robotic hysterectomy: a step towards future perspectives. Journal of Robotic Surgery, 2018, 12, 575-577.	1.8	24
28	Laparoscopic vs transvaginal cuff closure after total laparoscopic hysterectomy: a randomized trial by the Italian Society of Gynecologic Endoscopy. American Journal of Obstetrics and Gynecology, 2018, 218, 500.e1-500.e13.	1.3	58
29	Single-Institution Propensity-Matched Study to Evaluate the Psychological Effect of Minimally Invasive Interval Debulking Surgery Versus Standard Laparotomic Treatment: From Body to Mind and Back. Journal of Minimally Invasive Gynecology, 2018, 25, 816-822.	0.6	45
30	Robotic video endoscopic inguinal lymphadenectomy (R-VEIL) for vulvar cancer with sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology. Gynecologic Oncology, 2018, 150, 203-204.	1.4	8
31	The Senhanceâ„¢ surgical robotic system (â€œSenhanceâ€) for total hysterectomy in obese patients: a pilot study. Journal of Robotic Surgery, 2018, 12, 229-234.	1.8	60
32	Laparoscopic Pelvic Exenteration With Radical Vaginectomy Using 3-Dimensional Vision and Multifunction Instrument. International Journal of Gynecological Cancer, 2018, 28, 1805-1806.	2.5	5
33	Laparoscopic vs Transvaginal Cuff Closure After Total Laparoscopic Hysterectomy: A Randomized Trial by the Italian Society of Gynecologic Endoscopy. Obstetrical and Gynecological Survey, 2018, 73, 520-522.	0.4	0
34	Treatment of gynecological disease in obese patient: which role for telelap ALF-X platform?. Journal of Robotic Surgery, 2017, 11, 95-96.	1.8	4
35	Preoperative Serum Human Epididymis Protein 4 Levels in Early Stage Endometrial Cancer: A Prospective Study. International Journal of Gynecological Cancer, 2017, 27, 1200-1205.	2.5	8
36	Reply. Journal of Minimally Invasive Gynecology, 2017, 24, 683-684.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Laparoscopic, minilaparoscopic, single-port and percutaneous hysterectomy: Comparison of perioperative outcomes of minimally invasive approaches in gynecologic surgery. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 216, 125-129.	1.1	51
38	Needleoscopic Conservative Staging of Borderline Ovarian Tumor. <i>Journal of Minimally Invasive Gynecology</i> , 2017, 24, 529-530.	0.6	26
39	Role of blue dye for sentinel lymph node detection in early endometrial cancer. <i>Gynecological Surgery</i> , 2017, 14, 23.	0.9	21
40	Total Laparoscopic (S-LPS) versus TELELAP ALF-X Robotic-Assisted Hysterectomy: A Case-Control Study. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 933-938.	0.6	37
41	The surgical outcome of intracapsular cesarean myomectomy. A match control study. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2014, 27, 66-71.	1.5	45
42	Bladeless Direct Optical Trocar Insertion in Laparoscopic Procedures on the Obese Patient. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2013, 17, 521-528.	1.1	38
43	Automatic Evaluation of Progression Angle and Fetal Head Station through Intrapartum Echographic Monitoring. <i>Computational and Mathematical Methods in Medicine</i> , 2013, 2013, 1-8.	1.3	8
44	Sonographic markers for early diagnosis of fetal malformations. <i>World Journal of Radiology</i> , 2013, 5, 356.	1.1	25
45	Senhance robotic platform for ovarian borderline tumor treatment: minimally invasive robotic approach for conservative adnexal surgery. <i>Gynecology and Pelvic Medicine</i> , 0, 3, 27-27.	0.1	2